Valeant Pharma Gets a Hold Rating from H.C. Wainwright


H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Valeant Pharma (NYSE: VRX) today and set a price target of $20. The company’s shares closed yesterday at $22.

According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.4% and a 40.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Valeant Pharma has an analyst consensus of Hold, with a price target consensus of $19.82.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.43 and a one-year low of $10.94. Currently, Valeant Pharma has an average volume of 8.15M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.

Read More on VRX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts